Metastatic low-grade endometrial stromal sarcoma with sex cord and smooth muscle differentiation: A case report

被引：7
作者：
Zhu, Qi [1 ]
Sun, Yan-Qin [1 ,2 ]
Di, Xiao-Qing [1 ,2 ]
Huang, Bing [1 ,2 ]
Huang, Jian [1 ,2 ]
机构：
[1] Guangdong Med Univ, Affiliated Hosp, Ctr Pathol Diag & Res, 57 South Renmin Ave, Zhanjiang 524023, Guangdong, Peoples R China
[2] Guangdong Med Univ, Dept Pathol, Dongguan 523808, Guangdong, Peoples R China
来源：
WORLD JOURNAL OF CLINICAL CASES | 2019年 / 7卷 / 02期
关键词：
Endometrial stromal sarcoma; Sex cord-like; Smooth muscle-like; Pathological changes; Immunohistochemistry; Case report; TUMORS;
D O I：
10.12998/wjcc.v7.i2.221
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BACKGROUND Metastatic low-grade endometrial stromal sarcoma (LG-ESS) with sex cord-like and smooth muscle-like differentiation is rare. This article reports such a case with multiple recurrences and with extensive pelvic and abdominal metastasis. CASE SUMMARY A 47-year-old female patient was diagnosed with multiple cystic masses in the pelvic cavity by magnetic resonance imaging examination. Based on the postoperative pathological and immunohistochemical analyses of the surgical specimen, she was diagnosed with a metastatic low-grade endometrial stromal sarcoma with sex cord and smooth muscle differentiation. CONCLUSION LG-ESS is a low-grade malignant tumor with a high recurrence rate and metastasis probability. It is easily misdiagnosed initially. It is essential to distinguish LG-ESS with sex cord-like differentiation from uterine tumour resembling ovarian sex cord tumour.
引用
收藏
页码：221 / 227
页数：7
相关论文
共 9 条
[1]  
CLEMENT PB, 1976, AM J CLIN PATHOL, V66, P512
[2]  
Kurman RJ, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P1, DOI 10.1007/978-1-4419-0489-8
[3]  
Kurman RJ, 2014, WHO CLASSIFICATION T, P141
[4]   CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms [J].
McCluggage, WG ;
Sumathi, VP ;
Maxwell, P .
HISTOPATHOLOGY, 2001, 39 (03) :273-278
[5]  
Mukhopadhyay M, 2017, J CLIN DIAGN RES, V11, pED3, DOI 10.7860/JCDR/2017/24924.9370
[6]  
Richmond AM, 2017, GYNECOL ONCOL REP, V19, P34, DOI 10.1016/j.gore.2016.12.002
[7]  
Sato Saki, 2018, Kobe J Med Sci, V64, pE36
[8]  
Schraag SM, 2017, GYNECOL ONCOL REP, V19, P53, DOI 10.1016/j.gore.2017.01.004
[9]  
Yenicesu O, 2018, J EXP THER ONCOL, V12, P281
1